U.S. patent application number 13/726289 was filed with the patent office on 2013-12-19 for culturing circular ssdna viruses for the production of vaccines.
The applicant listed for this patent is Sven ARNOUTS, Gerald MISINZO, Hans NAUWYNCK. Invention is credited to Sven ARNOUTS, Gerald MISINZO, Hans NAUWYNCK.
Application Number | 20130336927 13/726289 |
Document ID | / |
Family ID | 46045599 |
Filed Date | 2013-12-19 |
United States Patent
Application |
20130336927 |
Kind Code |
A1 |
NAUWYNCK; Hans ; et
al. |
December 19, 2013 |
CULTURING CIRCULAR ssDNA VIRUSES FOR THE PRODUCTION OF VACCINES
Abstract
The present invention relates to the use of interferon in the in
vitro cultivation of animal circular ssDNA virus such as Porcine
Circovirus 2 or human TT virus in an animal cell line. Increased
titres of animal circular ssDNA virus are obtained by addition of
interferons or agents which ensure the production of endogenous
interferons by said cell line and/or by the reduction of
endosomal-lysosomal system acidification.
Inventors: |
NAUWYNCK; Hans; (Zomergem,
BE) ; MISINZO; Gerald; (Sengerema, TZ) ;
ARNOUTS; Sven; (Bertem, BE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
NAUWYNCK; Hans
MISINZO; Gerald
ARNOUTS; Sven |
Zomergem
Sengerema
Bertem |
|
BE
TZ
BE |
|
|
Family ID: |
46045599 |
Appl. No.: |
13/726289 |
Filed: |
December 24, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12321755 |
Jan 23, 2009 |
|
|
|
13726289 |
|
|
|
|
11680420 |
Feb 28, 2007 |
7566562 |
|
|
12321755 |
|
|
|
|
11275842 |
Jan 31, 2006 |
7300785 |
|
|
11680420 |
|
|
|
|
60649738 |
Feb 3, 2005 |
|
|
|
Current U.S.
Class: |
424/85.4 ;
424/204.1 |
Current CPC
Class: |
A61K 2039/55522
20130101; A61K 38/21 20130101; C12N 2750/10034 20130101; A61P 31/12
20180101; A61K 39/12 20130101; A61K 2039/552 20130101; A61P 37/04
20180101; A61K 2039/5254 20130101; C12N 7/00 20130101; A61K 39/39
20130101 |
Class at
Publication: |
424/85.4 ;
424/204.1 |
International
Class: |
A61K 39/12 20060101
A61K039/12; A61K 38/21 20060101 A61K038/21 |
Claims
1-30. (canceled)
31. A method of improving the immune response of a subject to a
vaccine comprising an attenuated animal circular ssDNA virus, said
method comprising, administering one or more inhibitors of
endosomal-lysosomal system acidification to said subject,
simultaneously with or shortly before or after administering said
vaccine to said subject.
32. The method of claim 31, which further comprises administering
interferon to said subject, simultaneously with or shortly before
or after administering said vaccine.
33. The method according to claim 31, wherein said animal circular
ssDNA virus is a Circovirus.
34. A vaccine comprising an attenuated animal circular ssDNA virus
and one or more inhibitors of endosomal-lysosomal system
acidification.
35. The vaccine of claim 34, which further comprises an
interferon.
36. A vaccine comprising an attenuated animal circularssDNA virus
and interferon.
37. An undiluted medium of an in vitro culture of a cell-line
comprising animal circular ssDNA virus characterized in that it
further comprises at least 2 U/ml interferon.
38. An undiluted medium of an in vitro culture of a cell-line
comprising animal circular ssDNA virus characterized in that it
further comprises an agent capable of inhibiting
endosomal-lysosomal system acidification.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 11/680,420, filed Feb. 28, 2007, which is a
continuation-in-part of U.S. patent application Ser. No.
11/275,842, filed Jan. 31, 2006, which, in turn, claims benefit of
U.S. Provisional Application Ser. No. 60/649,738, filed Feb. 3,
2005, the disclosures of which are incorporated by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to cell culture methods for
the in vitro cultivation of viruses (more in particular animal
circular ssDNA viruses), which are of use in the production of
vaccines, as well as the vaccines produced. The invention further
relates to in vitro methods for the diagnosis of animal circular
ssDNA viral infection.
BACKGROUND
[0003] Animal circular ssDNA viruses are a group of viruses of
pathogenic importance. Human circular ssDNA viruses have been
detected in patients with hepatitis of unknown aetiology. The titre
of human TTV virus is also significantly higher in HIV-infected
patients with AIDS, AIDS patients with a low CD4 T cell count, or
patients with high HIV viral loads [Shibayama et al. (2001) AIDS
15, 563-570]. Touinssi et al. [J. Clin Virol. (2001) 21, 135-141]
report a relationship between the prevalence of elevated viral
loads of TTV virus and the level of immunocompetence of the
populations studied and suggest that stimulation of the immune
system by an interferon treatment was able to clear TTV viraemia.
Moreno et al. (World J Gastroenterol (2004) 1, 143-146) however
found that administration of PEG-IFN plus ribovarin could not
induce a TTV sustained response in patients infected with hepatitis
C.
[0004] Porcine circoviruses are associated with the occurrence of
postweaning multisystemic wasting syndrome (PMWS) in pigs. Porcine
circovirus 2 (PCV2) is a member of the family of Circoviridae. It
is a very small virus with a relatively simple structure. The PCV2
viral genome does not code for a viral DNA-polymerase, making it
dependent on cellular enzymes to complete its infectious cycle.
[0005] When PCV2 is inoculated in susceptible pigs, a high
variation in virus replication is observed. It has been observed
that PCV2 is able to replicate better in a host that is
simultaneously inoculated with other viruses such as porcine
reproductive and respiratory syndrome virus (PRRSV) [Allan et al.
(2000) Arch Virol. 145, 2421-2429] or porcine parvovirus (PPV)
[Allan et al. (2000) J Vet Med B. 47, 81-94]. A general stimulation
of the immune system with keyhole limpet hemocyanin [Krakowka et
al. (2001) Vet Pathol. 38, 31-42] has also been found to ameliorate
the replication of PCV2 in the host.
[0006] It has been shown for PCV2 that inhibition of
endosomal-lysosomal system acidification in a monocytic cell line
reduced PCV2 infection (Misinzo et al., 2005. J Gen Virol.
86:2057-68). These data demonstrated that PCV2 requires an acidic
environment for infection of a monocytic cell line.
[0007] Many cytokines are capable of modulating the susceptibility
of the host to a viral infection. The most studied and best
understood is the anti-viral effect of type I interferons
(IFN-alpha and IFN-beta). But also other cytokines such as tumour
necrosis factor alpha (TNF-alpha) and type II interferon
(IFN-gamma) have been shown to influence infection. The antiviral
effect of interferons has been demonstrated for many viruses and
has been found to be so consistent and potent that humans and
animals are routinely administered recombinant interferon
(IFN-alpha) for the treatment of viral infections.
SUMMARY OF THE INVENTION
[0008] The present invention is based on the surprising
observation, that type I and type II interferons have an enhancing
effect on the viral titre obtained in cell cultures after infection
in vitro with animal circular ssDNA virus, more particularly
porcine circovirus 2. In addition it was observed that, when
cultivating PCV2 in PK-15 epithelial cells in the presence of
inhibitors of endosomal-lysosomal system acidification, the viral
titre obtained in the cell cultures is further increased and this
independently of the effect of interferons. The combination of
interferons and endosomal-lysosomal system acidification inhibitors
generates a synergistic effect.
[0009] A first aspect of the present invention relates to the use
of an interferon-containing medium for the cultivation of animal
circular ssDNA virus in an animal cell line.
[0010] According to a first embodiment of this aspect of the
invention methods are provided for the in vitro cultivation of an
animal circular ssDNA virus comprising the step of inoculating
cells of a continuous animal cell line in a culture medium with the
circular ssDNA virus, thereby ensuring that the culture medium
contains interferon. Different methods for ensuring that the medium
contains interferon are envisaged. According to a specific
embodiment a method is provided for the in vitro cultivation of an
animal circular ssDNA virus comprising the steps of a) inoculating
cells of a cell line, more particularly a continuous animal cell
line, in culture medium with a circular ssDNA virus and b)
administering an exogenous interferon or an agent which induces the
endogenous production of an interferon by said cells. In view of
the fact that the object of the methods according to this aspect of
the invention is the generation of PCV2 viral particles, the
methods of the invention typically additionally comprise the step
of isolating PCV2 particles from the medium and/or infected cells
of the continuous animal cell line.
[0011] A second aspect of the present invention relates to the
cultivation of animal circular ssDNA virus in an animal cell line,
whereby it is ensured that endosomal-lysosomal system acidification
in the animal cell line is reduced.
[0012] Accordingly, the present invention provides methods for the
in vitro cultivation of an animal circular ssDNA virus comprising
the step of (a) inoculating cells of a continuous animal cell line
in a culture medium with the circular ssDNA virus, and (b)
cultivating the continuous animal cell line thereby ensuring that
endosomal-lysosomal system acidification is reduced in the
continuous animal cell line. As the object of the methods of the
invention is the generation of the animal circular ssDNA virus or
parts thereof, the methods of the invention generally comprise a
further step (c), wherein the animal circular ssDNA virus is
isolated from the medium and/or infected cells of the continuous
animal cell line.
[0013] Depending on the tools used to ensure the reduction of
endosomal-lysosomal system acidification, this can be ensured
before, during and/or after the inoculation with the circular ssDNA
virus.
[0014] In one embodiment of the methods of the invention, the
continuous animal cell line is cultivated in the presence of an
inhibitor of endosomal-lysosomal system acidification, more
particularly, a lysosomotropic agent capable of reducing
endosomal-lysosomal system acidification. Most particularly, the
use of ammonium chloride, chloroquine diphosphate and monensin as
lysosomotropic agents are envisaged.
[0015] In further particular embodiments, the methods of the
invention comprise the steps of: (a) inoculating cells of a
continuous animal cell line in culture medium with a circular ssDNA
virus and, (b) cultivating the inoculated continuous animal cell
line in the presence of an agent capable of inhibiting
endosomal-lysosomal system acidification.
[0016] Yet a further aspect of the present invention relates to the
use of both the presence of interferon and the effect of
endosomal-lysosomal system acidification for improving methods for
the cultivation of animal circular ssDNA virus in an animal cell
line.
[0017] Accordingly, methods are provided wherein a continuous
animal cell line, prior to, during or after inoculation, is
cultivated in the presence of Interferon and simultaneously or
sequentially reduction of endosomal-lysosomal system acidification
is ensured.
[0018] In one embodiment of this aspect of the invention, methods
are provided comprising the steps of (a) inoculating cells of a
continuous animal cell line in culture medium with a circular ssDNA
virus, (a') administering an exogenous interferon or an agent which
induces the endogenous production of an interferon by the cells of
the cell line and, (b) cultivating the continuous animal cell line
in the presence of an agent capable or inhibiting
endosomal-lysosomal system acidification, whereby the steps are not
necessarily in that order. Where the steps of the method are in
that order, the methods of the invention may optionally comprise,
between steps (a') and (b) a change of cultivation medium.
[0019] According to particular embodiments the methods according to
the different aspects of the invention are used for cultivating
viruses belonging to the group of Circoviruses, most particularly
Porcine Circovirus 2 (PCV2).
[0020] According to further particular embodiments of the methods
of the invention, the cell line use in the methods of the invention
is an non-human animal cell line, more particularly a porcine cell
line, such as, but not limited to PK-15, ST, SK or 3D4/31. In
particular embodiments, the cell line is an epithelial cell
line.
[0021] In particular embodiments, the methods of the invention
encompasses ensuring the presence of interferon in the medium of
the cell lines. This can be achieved either by contacting the cell
line with interferons, e.g. by adding one or more exogenous
interferons, such as interferon-alpha or interferon-gamma to the
medium. According to particular embodiments, the one or more
interferons are added to the culture medium at a concentration of
at least 2 U/ml medium. Addition of interferons to the medium can
be performed before, during or after inoculation of the cell line
with the animal circular ssDNA virus.
[0022] According to further embodiments of the methods of the
present invention which encompass ensuring the presence of
interferon in the medium of the cell lines, this is achieved by the
endogenous production of interferons by the continuous cell line.
In these embodiments, a continuous cell line capable of producing
interferons is used. The production of interferons can be inherent
to the animal cell line used or can be the result of transfection
with a polynucleotide which ensures interferon production, either
constitutively or by way of an inducible promoter whereby after
transfection, stimulation of the inducible promoter by an agent
results in interferon production by the cell line. Thus, according
to these embodiments a transgenic cell line, i.e. a cell line
comprising a foreign DNA which ensures production of interferon,
such as a foreign DNA encoding an interferon, is used in the
methods of the invention.
[0023] According to another aspect of the invention cultivation
media are provided which comprise both animal circular ssDNA virus
and at least 2 U/ml interferon and/or an agent capable of
inhibiting endosomal-lysosomal system acidification. According to
the present invention such media can be used for the development of
a vaccine.
[0024] Thus, according to yet another aspect of the invention
methods are provided for producing a vaccine. The methods of the
invention allow a more cost-efficient way of producing animal
circular ssDNA virus which can further be processed into a vaccine.
In one embodiment, the method for producing a vaccine will comprise
the steps of inoculating a continuous cell line with a circular
ssDNA virus and ensuring that the medium of the continuous cell
line comprises interferon, more particularly at a concentration of
at least 2 U/ml. In another embodiment, the methods for producing a
vaccine will comprise the steps of inoculating cells of a
continuous animal cell line in a culture medium with the circular
ssDNA virus, thereby ensuring, prior to and/or inoculation, the
reduction/inhibition of endosomal-lysosomal system acidification in
the continuous animal cell line. In yet a further embodiment, the
methods for producing a vaccine will comprise the steps of
inoculating cells of a continuous animal cell line in a culture
medium with the circular ssDNA virus thereby ensuring both that the
medium of the continuous cell line comprises interferon and that
endosomal-lysosomal system acidification in the continuous animal
cell line is reduced. The methods according to this aspect of the
invention further comprise the steps of allowing the ssDNA virus to
replicate in the continuous animal cell line; and obtaining the
circular ssDNA virus or components thereof from the continuous
animal cell line or said medium.
[0025] In the methods according to this aspect of the invention,
the step of ensuring that the medium of the continuous cell line
comprises interferon is in particular embodiments ensured by adding
an exogenous interferon to the medium of said continuous cell line
or adding an agent which ensures the endogenous production of an
interferon by the cell line; a further optional step comprises
allowing said ssDNA virus to replicate in said continuous animal
cell line; in further steps of the method of the present invention,
the circular ssDNA virus or components thereof are isolated from
the continuous cell line and/or the medium of the cell line and
used in the development of a vaccine.
[0026] In the methods according to this aspect of the invention,
the step of ensuring the reduction of endosomal/lysosomal system
acidification of the continuous animal cell line is, in particular
embodiments ensured by addition of lysosomotropic
endosomal/lysosomal acidification inhibitors to the cultivation
medium. Most particularly, lysosomotropic endosomal/lysosomal
acidification inhibitors are used.
[0027] According to yet another aspect the invention provides in
vitro methods for determining the infection of a animal or a cell
culture by an animal circular ssDNA virus. Such methods involve
increasing the amount of virus before detection. Different
embodiments of this method are envisaged within the context of the
invention. In a particular embodiment the amount of virus in the
sample is increased before detection by using interferon. In other
embodiments, this increase is ensured by ensuring that
endosomal-lysosomal system acidification is reduced. In a further
embodiment, the increase in virus titre is ensured by the combined
use of interferon and reduction of endosomal-lysosomal system
acidification.
[0028] According to one embodiment of this aspect of the invention,
methods are provided whereby the amount of virus is directly
increased in the sample (or a fraction thereof) of the animal or
the culture. This method is particularly suited for samples of
animals and cell cultures that comprise cells, more particularly
comprising cells which are susceptible to infection by the circular
ssDNA virus (such as, but not limited to blood or ascites samples
or cell-comprising culture samples). Typically according to this
embodiment, the method can comprise one or more steps comprising
adding interferon or an agent capable of inducing interferon to a
cell-containing sample (or a fraction thereof) of said animal or
cell culture and/or reducing endosomal-lysosomal system
acidification in the continuous animal cell line. The methods
further comprise the steps of allowing the replication of the
circular ssDNA virus in the sample, and detecting the presence of
the circular ssDNA virus in the sample.
[0029] Alternatively, the amount of virus in the sample is
increased indirectly, through the intermediate of a cell line
susceptible to infection by the animal circular ssDNA virus. This
method can also be used to detect the presence of circular ssDNA
virus in a sample which does not comprise cells, more particularly
does not comprise cells susceptible to infection by the circular
ssDNA virus (eg. supernatant or serum). Typically, according to
this embodiment, the method can comprise the steps of adding the
sample (or fraction thereof) for which the detection is to be
performed to a culture of cells susceptible to infection by
circular ssDNA virus (or visa versa). The titre of the virus is
then increased e.g. by adding interferon to the latter mixture
(comprising the culture of susceptible cells and the sample) and/or
endosomal-lysosomal system acidification inhibitors and detecting
of the presence of ssDNA virus in the medium of the culture of
cells. Alternatively, the susceptible cells are cells which produce
interferon either naturally or as a result of genetic modification.
Additionally or alternatively, the susceptible cells are cells in
which the endosomal-lysosomal system acidification is reduced as a
result of a selection and/or genetic modification.
[0030] In the above-described methods, detection of animal circular
ssDNA virus is indicative of the infection of the sample by the
animal circular ssDNA virus.
[0031] The above methods represent an improvement over current
detection methods of circular ssDNA virus in animal and cell
culture samples, as the sensitivity is increased. Thus the present
invention provides improvements of viral detection methods whereby
the increase in sensitivity of at least .times.2 is observed,
compared to detection in the absence of IFN and reduction of
endosomal-lysosomal system acidification.
[0032] In particular embodiments of the methods of the present
invention, the interferon used is IFN-alpha and/or IFN-gamma.
[0033] According to yet another aspect of the present invention,
methods are provided to improve the immune response in an animal to
a vaccine against an animal circular ssDNA virus. In particular
embodiment these methods comprise administration of interferon to
the animal, wherein the interferon ensures the improved immune
response to said vaccine. In another embodiment, these methods
comprise administration of endosomal-lysosomal system acidification
inhibitors to the animal, resulting in an improved immune
response.
[0034] Such methods can additionally comprise the step of
administering a vaccine against an animal circular ssDNA virus to
the animal, whereby the administration of interferon and/or
endosomal-lysosomal system acidification inhibitors can occur
sequentially to (shortly, most particularly within 24 hrs, before
or after) or simultaneously with the administration of the vaccine.
Such methods can optionally further comprise identifying an animal
in need of such an improved immune response, either before or after
administration of the vaccine thereto.
[0035] Thus the present invention provides the use of one or more
interferons and/or endosomal-lysosomal system acidification
inhibitors in the manufacture of a medicament for the improvement
of the immune response to the vaccination with an attenuated animal
circular ssDNA virus. A specific embodiment of the invention the
animal circular ssDNA virus is a Circovirus.
[0036] According to this aspect of the invention, vaccines are
provided comprising both an attenuated animal circular ssDNA virus
and interferon and/or endosomal-lysosomal system acidification
inhibitors. Alternatively, kits for vaccination are provided which
comprise a) a composition comprising an attenuated animal circular
ssDNA virus vaccine and b) an interferon and/or one or more
endosomal-lysosomal system acidification inhibitors for
simultaneous or sequential administration to an animal.
DETAILED DESCRIPTION OF THE INVENTION
[0037] The present invention relates to the in vitro cultivation of
animal circular ssDNA viruses. The term "animal circular ssDNA
virus" is used to refer to a subgroup of animal single strand DNA
(ssDNA) viruses, which infect eukaryotic non-plant hosts, and which
have a circular genome. Thus, the animal circular ssDNA viruses are
to be distinguished from ssDNA viruses that infect prokaryotes
(i.e. Microviridae and Inoviridae) and from ssDNA viruses that
infect plants (i.e. Geminiviridae and Nanoviridae). At the same
time they are to be distinguished from linear ssDNA viruses that
infect non-plant eukaryotes (i.e. Parvoviridiae). In the present
invention "non-plant" and "animal" will be used as synonyms,
whereby "animal" will include human, unless specified as
"non-human".
[0038] The group of circular animal ssDNA viruses encompasses both
the Anelloviruses and the Circoviridae. Whether the taxonomic group
of the Anelloviruses should be placed within or next to the group
of Circoviridae has not yet been completely established.
Anellovirus members are at present not yet included in the official
classification of the ICTV (International Committee on Taxonomy of
Viruses) [see Biagini (2004) Vet. Microbiol. 98, 95-2004].
[0039] The Circoviridae represents a taxonomic group which
comprises both Circovirus and Gyrovirus. Examples of Circovirus are
Psittacine Beak and Feather Disease Virus, Bovine circovirus,
Canary circovirus, Columbid circovirus, Goose circovirus, Mulard
duck circovirus, Muscovy duck circovirus, and Porcine circovirus
(Porcine circovirus 1 (PCV-1) and Porcine circovirus 2 (PCV2)).
[0040] "PCV2" or Porcine circovirus 2, is a very small virus with a
relatively simple structure. The circular ambisense 1.7 Kb genome
codes for two major proteins. On the viral strand, open reading
frame (ORF) 2 codes for the capsid protein and on the complementary
strand, ORF1 codes for two non-structural proteins Rep and Rep'
which form a complex that is involved in the replication of the
genome. Besides these three viral proteins, no others have been
characterised to this date. The fact that PCV2 does not code for a
viral DNA-polymerase, makes it dependent of cellular enzymes to
complete its infectious cycle. Many different strains, isolated
from PMWS-affected pigs, healthy pigs or aborted foetuses have been
characterized.
[0041] The taxonomic group of the Anellovirus comprises the SEN
virus, the Sentinel virus, the ITV-like mini virus and the TT
virus. Different types of TT virus have been described including TT
virus genotype 6, TT virus group, TTV-like virus DXL1 and TTV-like
virus DXL2.
[0042] In the context of the present invention, the term `virus`
(such as when referring to an animal circular ssDNA virus can be
used to refer to either or both wild-type isolates and/or
spontaneously or purposefully mutated laboratory strains. According
to a particular embodiment, a virus is an attenuated virus.
[0043] The present invention relates to the cultivation of animal
circular ssDNA virus in an animal cell line, especially a
continuous cell line. The animal cell lines envisaged within the
context of the present invention preferably encompass any cell line
that can be passaged multiple times (e.g. at least 10 times) in
vitro and which can be infected by a circular animal ssDNA virus.
The suitability of a cell line for use in the context of the
present invention can be investigated by assaying the presence of
circular animal ssDNA viral proteins (immunostaining) or circular
animal ssDNA viral DNA (hybridisation or PCR amplification) after
infection of said cell line with an animal circular ssDNA virus.
The term cell line in the context of the present invention
encompasses both transfected and non-transfected cell lines.
[0044] Inoculation or infection of a susceptible animal cell line
by an animal circular ssDNA virus can be achieved by routine
methods. Typically inoculation is performed as described herein
using a strain of circular ssDNA virus at a multiplicity of
infection ranging from about 0.01 to about 1. The virus is usually
diluted in MEM and inoculated on the cell cultures by incubating
cells and virus for 1 hour at 37.degree. C. After 1 hour, new
culture medium is added.
[0045] A particular embodiment of the present invention relates to
the cultivation of PCV2 in continuous animal cell lines in vitro.
According to one embodiment of the invention, the cell lines are
porcine cell lines. PCV2 is able to replicate in most porcine cell
lines in vitro. Most particularly, the cell lines envisaged in the
context of the present invention are immortalised porcine cell
lines such as, but not limited to the porcine kidney epithelial
cell lines PK-15 and SK, the monomyeloid cell line 3D4/31 and the
testicular cell line ST. PCV2 is also able to replicate to a lesser
extent in CHO cells (Chinese hamster ovaries). A number of
non-porcine cell lines are resistant to PCV2-infection: MARC-145,
MDBK, RK-13, EEL). Additionally or alternatively, particular
embodiments of the methods of the invention make use of an animal
cell line which is an epithelial cell line, i.e. a cell line of
cells of epithelial
[0046] Another embodiment of the present invention relates to the
cultivation of TTvirus in animal cell lines in vitro. In the
context of this embodiment continuous cell lines susceptible to
infection with TTvirus are envisaged. Such cells lines can be, but
are not limited to cell lines of human or primate origin, such as
human or primate kidney carcinoma cell lines.
[0047] A particular embodiment of the present invention relates to
the cultivation of PCV2 in continuous animal cell lines, for the
production of vaccines, more particularly vaccines for use in pigs.
When referring to "Pigs" in the context of the present invention,
reference is made to a member of the Suidae, more particularly, any
race or strain of Sus scrofa domestica. It includes free living and
domesticated pigs. It also includes to pigs, which underwent a
special regimen such as SPF (Specific Pathogen Free) pigs, or
gnotobiotic pigs (gnotobiotic piglets (caesarian-derived,
colostrum-deprived, raised in a germ-free environment).
[0048] The present invention refers to a method for the in vitro
cultivation of an animal circular ssDNA virus. According to a
particular embodiment the circular ssDNA virus is a member of the
Circoviridae or is an Annelovirus. In a particular embodiment of
the present invention, the circular ssDNA virus is a Circovirus,
most particularly PCV2. More particularly, the method of the
invention is demonstrated for the cultivation of PCV2 strain
Stoon-1010. This strain was isolated from the first described case
of PMWS and can therefore be considered to be the reference
strain.
[0049] According to a first aspect of the present invention
improved cultivation of the circular ssDNA virus (i.e. increased
virus titre) is obtained in vitro by infection of a continuous
animal cell line with the circular ssDNA virus in the presence of
an interferon. Interferons useful in the context of the present
invention include Type I and Type II interferons. According to a
particular embodiment of the present invention, IFN-gamma is used.
Apart from wild type interferons (isolated from mammalian or
bacterial cells or recombinant), the invention can also be
performed with modified versions (mutated and/or truncated
versions) of an interferon, as long as the IFN remains active in
one of the bioassays known to the skilled person, such as, but not
limited to the one described herein for IFN-alpha.
[0050] According to a particular embodiment of the invention the
method encompasses the addition of one or more exogenous
interferons to the cell culture. The term `exogenous` in this
context means that the interferon(s) is(are) not produced by the
cell line itself but added directly or indirectly to the
medium.
[0051] The concentration of interferons added to the culture of
animal circular ssDNA viruses according to the present invention is
a concentration of at least 2 U/ml, particularly at least 50 U/ml,
more particularly at least 100 U/ml. Typical concentrations of
IFN-gamma added to large scale production units will be around
250-500 U/ml, but most likely even higher concentrations will
further increase virus titres.
[0052] The addition of exogenous interferons can be achieved in
different ways. According to a particular embodiment of the
invention, the cytokine is added in purified form, e.g. from a
cytokine stock as described above. Alternatively, however, the
interferon can be present in a medium, e.g. as obtained from a cell
culture which produces interferon. Typically, immunological cells
are capable of producing interferons when stimulated. An exemplary
source of IFN may be the medium of PBMCs, or of any specific cell
type producing a type of IFN such as but not limited to leukocytes,
fibroblasts, epithelial cells, macrophages, lymphocytes,
plasmacytoid dendritic cells, and bacterial cells. Compounds which
are known to induce IFN production in certain cell types and which
can be used in the context of the present invention include, but
are not limited to concanavalin A,
12-O-tetradecanoyl-phorbol-13-acetate, IL-2, Poly I:C.
Alternatively, interferon production can be induced in a number of
cell types by infection with a micro-organism or foreign agent,
e.g. of viral, bacterial or parasitic origin or contacting the
cells with non-infectious proteins. Methods to induce IFN
production in cultures by viruses have been described, e.g. in U.S.
Pat. No. 3,951,740. Such a virus can be a second animal virus, such
as porcine reproductive and respiratory syndrome virus (PRRSV) or
porcine parvovirus (PPV). Alternatively, e.g. in the case of human
cells, the other virus can be an animal virus such as Hepatitis C
virus or HIV.
[0053] According to a further embodiment of the present invention
the method for cultivating animal circular ssDNA virus encompasses
ensuring the production of interferons by the cell line itself,
i.e. the production of endogenous interferons.
[0054] A limited number of continuous cell lines are capable of
producing interferons, such as, but not limited to lymphoblastoid
cell lines (e.g. Namalva cell lines producing "Namalva
interferon"). Most continuous animal cell lines however do not
naturally produce interferons. Nevertheless, the present invention
also envisages cell lines capable of producing interferon as a
result of transfection. Cell lines capable of producing IFN as a
result of genetic manipulation are generally referred to herein as
transgenic cell lines. Such a production of one or more interferons
by transfected cell lines can be either constitutive or inducible.
Methods of transfecting cell lines suitable in the context of the
present invention, such as, but not limited to the PK15 cell line,
are known in the art. The cloning and expression of porcine
interferon alpha and gamma is described in Xia et al (2005) Vet
Immunol Immunopathol. 104, 81-89. Alternatively, a wide variety of
vectors for the recombinant expression of genes in eukaryotic cells
are available from e.g. Clontech, InVitrogen, Stratagene. DNA
sequences encoding porcine interferon gamma [NM.sub.--213948] and
interferon alpha [NM.sub.--214393] are deposited in Genbank.
[0055] Protocols for the transfection of cell are described in e.g.
Cell Biology: A Laboratory Handbook (1998) Ed. J. Celis, Academic
Press, or are available from the manufacturers of transfecting
agents (eg Fugene (Roche Diagnostics) or electroporation apparatus
(e.g. BioRad).
[0056] According to this aspect of the invention endogenous
production of interferon by the cell line is ensured by
transfection of the cell line and, in the case of inducible
promoters, induction of the inducible interferon production by a
compound which is capable of activating the inducible promoter.
[0057] The amount of interferon used or observed in the context of
the present invention will be referred to as a concentration (i.e.
amount/ml). A concentration can be expressed in weight (mg/ml) or
molarity (M) or by activity (Units/ml).
[0058] Assays for determining activity in Units/ml are known in the
art. As there is no standard for porcine interferon, the units of
porcine interferons are usually determined with respect to the
international reference standard for the corresponding human
interferon. For instance the units of porcine interferon alpha is
determined with respect to the activity of human leukocyte
interferon (Ga23-902-530) provided by the National Institutes of
Health [see Pestka, S. (1986) Methods in Enzymology 119, 14-23].
The activity of porcine IFN-alpha can be determined using the
cytopathic effect inhibition assay as described by Rubinstein et al
S. [(1981) J. Virol. 37, 755-758] and Famillett et al. [(1981)
Methods in Enzymology 78, 387-394]. In such an antiviral assay
about 1 unit/ml of interferon is the quantity necessary to produce
a cytopathic effect of 50%.
[0059] In the context of the present invention, interferon
concentrations will refer to the exogenously added interferon as
calculated over the amount of cell culture medium. Alternatively,
when IFN is produced endogenously by the cell line according to a
particular embodiment of the invention, IFN concentrations in the
medium will reflect the amount of interferon produced by the cells
which are present in the cell culture medium. The activity and
concentration of interferon(s) can be assayed by quantitative
measurements (e.g. ELISA) or by qualitative measurements
(bioassays).
[0060] Thus, typically the medium of the continuous cell lines used
to produce animal circular ssDNA viruses according to the present
invention will contain one or more interferons at a concentration
of at least 2 U/ml, more particularly at least 20 U/ml, even more
particularly at least 100 U/ml, most particularly 500 U/ml or
more.
[0061] Where the interferon is exogenously added or endogenous
production can be controlled (e.g. use of an inducible promoter),
according to particular embodiments of the methods of the present
invention, the time periods envisaged for contacting the cells with
interferon will be between 30 minutes and 48 hrs or more. It will
be understood that the time period is determined at least in part
by the concentration of IFN used or envisaged to be produced by the
cells. More particularly, a time period of 24 hrs incubation in the
presence of 100-500 U/ml interferon is envisaged.
[0062] According to another aspect of the invention, improved
cultivation of the circular ssDNA virus (i.e. increased virus
titre) is obtained in vitro by infection of a continuous animal
cell line with the circular ssDNA virus and inhibiting (with the
aim of at least reducing) endosomal-lysosomal system acidification
in the cells. The endosomal-lysosomal system consists of membrane
bound organelles that functions in the cellular housekeeping by
internalization, sorting, and breakdown of macromolecules (Mellman,
I. 1996. Annu. Rev. Cell Dev. Biol. 12, 575-625). The
endosomal-lysosomal system is composed of primary endocytic
vesicles, early endosomes, late endosomes, and lysosomes. The
endosomal-lysosomal system is characterized by gradual
acidification of its vesicles as they mature from early endosomes
into lysosomes. It has been found that reduction of
endosomal-lysosomal system acidification increases susceptibility
of certain cells to PCV2 infection.
[0063] Accordingly, the present invention envisages methods whereby
endosomal-lysosomal system acidification is reduced or inhibited.
Endosomal-lysosomal system acidification can be inhibited by
lysosomotropic agents. The term `lysosomotropic` as used herein
designates all substances that are taken up selectively into
lysosomes irrespective of their chemical structure or mechanism of
uptake (De Duve et al., 1974. Biochem. Pharmacol. 23:2495-2531).
The pH of endosomal and/or lysosomal vesicles can be measured by
methods known to the skilled person (such as, but not limited to
described inter alia by Maxfield et al. 1982, J. Cell Biol. Vol
95:676-681; Ohkuma and Poole 1987, Proc. Natl Acad Sci USA
75:3327-3331). In particular embodiments the reduction of
acidification envisaged corresponds to an increase of pH of at
least 0.5 units, more particularly 1 unit or more.
[0064] According to one embodiment, a lysosomotropic agent is used,
more particularly a lysosomotropic acidification-inhibiting agent,
i.e. a lysosomotropic agent capable of changing the acidic pH of
the lysosomes and/or other vesicles within the endosomal-lysosomal
system. Lysosomotropic agents, such as chloroquine diphosphate,
ammonium chloride and monensin raise pH within lysosomes, thereby
also resulting in an increased pH. It has been found in the present
invention that reduction of endosomal-lysosomal system
acidification by treatment of cells with lysosomotropic agents
capable of raising the pH within the endosomal-lysosomal system
increases the susceptibility of cells to PCV2 infection.
Particularly, suitable lysosomotropic agents for use in the methods
of the present invention thus include, but are not limited to,
ammonium chloride, chloroquine diphosphate and monensin.
[0065] Further examples of suitable inhibitors of
endosomal-lysosomal acidification include tamoxifen (Nihal et al.,
1999. Proc Natl Acad Sci USA 96(8):4432-7), bafilomycins and
concanamycins (Drose & Altendorf. 1997. J. Exp. Biol. 200:1-8),
nigericin,
N-(3-[(2,4-dinitrophenyl)-amino]-propyl)-N-(3-aminopropyl-methylamine)dih-
ydrochloride (DAMP) (Anderson et al., 1984. Proc Natl Acad Sci USA
81:4838-4842), primaquine (DeDuve et al., 1974, Biochem Pharmacol
23:2495-2531), methylamine, Destruxin B (Muori et al., 1994.
Biochem Biophys Res Commun 205:1358-1365).
[0066] According to another embodiment, endosomal acidification is
reduced or inhibited by other means, such as, but not limited to,
exposure to cadmium or pyocyanin (produced by Pseudomonas
aeruginosa) or other agents that directly inhibit V-type H+-ATPase
(proton pump; V-ATPase), e.g. bafilomycins and concanamycins,
and/or inhibit intracellular vesicle trafficking within the
endosomal-lysosomal system; specific antibiotics such as duramycin
and azithromycin capable of inhibiting acidification of the
endosomal-lysosomal system; Amphotericin B, an antifungal drug,
which blocks the fusion between endosomes and/or the fusion between
endosomes and lysosomes; infection with Rhodococcus equi and
Francisella tularensis, bacteria that have been described to
survive a phagolysosomal environment by suppressing acidification
of the phagolysosome (Clemens et al., 2004. Infect Immun.
72:3204-17; Toyooka et al., 2005. J Med Microbiol. 54:1007-15);
finally the infection of cell lines carrying genetic modifications
resulting in loss of function of proteins involved in endosome
acidification machinery is also envisaged, including cell lines
which naturally or via selection have defective endosome
acidification (such as CHO mutants DTG 1-5-4 and DTF 1-5-1 (Robbins
et al. 1983, J. Cell Biol. 99:1296-1308)).
[0067] Accordingly, according to this aspect of the invention,
methods are provided for the in vitro cultivation of an animal
circular ssDNA virus comprising the step of inoculating cells of a
continuous animal cell line in a culture medium with said circular
ssDNA virus, while inhibiting endosomal-lysosomal acidification. In
a particular embodiment, the reduction of endosomal-lysosomal
acidification is ensured by cultivating the cells in the presence
of a pH stabilizing agent. More particularly, the pH stabilizing
agent is a lysosomotropic agent capable of inhibiting acidification
within lysosomes.
[0068] Where a stabilizing agent is used according to the methods
of the present invention, incubation of the continuous cell line
with the stabilizing agent can be performed prior to,
simultaneously with, or subsequent to PCV2 inoculation of the
cells. According to a particular embodiment, the cells are treated
with one or more stabilizing agents after PCV2 inoculation.
[0069] The amount of stabilizing agent used in the methods of the
invention is determined by the nature and characteristics of the
agent used. Where the use of lysosomotropic agents is envisaged,
the amount of agent is typically between 0.1 .mu.M and 200 mM. The
present invention demonstrates that significant enhancement of PCV2
infection can be obtained by using 25 mM ammonium chloride, 125
.mu.M chloroquine diphosphate and/or 6 .mu.M monensin. Typically
incubation with stabilizing agents takes place for a period between
30 min and 2-5 days. Most particularly an incubation time of 24 hrs
with the agents of the invention is envisaged.
[0070] Where other methods of inhibiting endosomal-lysosomal system
acidification are used, other concentrations and/or time periods of
incubation may be appropriate. These can be easily optimized by the
skilled person by optimization experiments as performed for the
lysosomotropic agents described herein.
[0071] According to a further aspect of the invention, improved
cultivation of the circular ssDNA virus (i.e. increased virus
titre) is obtained in vitro by infection of a continuous animal
cell line with the circular ssDNA virus in the presence of an
interferon and reduction of endosomal-lysosomal system
acidification in the cells. According to this aspect, the effect of
endosomal-lysosomal system acidification reduction and the presence
of an interferon on the susceptibility of cells to PCV2 infection
is combined. More particularly the combined use of
endosomal-lysosomal system acidification inhibitors and IFN
generates a synergistic effect on PCV2 production.
[0072] Accordingly, according to this aspect of the invention,
methods are provided for the in vitro cultivation of an animal
circular ssDNA virus comprising the step of inoculating cells of a
continuous animal cell line in a culture medium with said circular
ssDNA virus, in the presence of interferon, as described
hereinabove, and cultivating the continuous animal cell line while
inhibiting endosomal-lysosomal system acidification. Generally, the
methods according to this aspect of the invention involve a
combination of the methods of cultivation in the presence of IFN
and the methods of cultivation whereby endosomal-lysosomal system
acidification is inhibited as described in the sections above.
According to one embodiment the addition of interferon and the
reduction of endosomal-lysosomal system acidification is performed
simultaneously. Alternatively, the addition of interferon and the
reduction of endosomal-lysosomal system acidification can be
performed in subsequent steps, either in the same medium or with
intermediate removal of the cultivation medium. According to a
particular embodiment of the present invention, the cells are
contacted with interferon prior to the inoculation with PCV2,
whereafter the cultivation medium is changed and an agent ensuring
inhibition of endosomal acidification is added to the new medium
(with or without interferon) for further cultivation. Where
presence of IFN is ensured by endogenous production of IFN by the
cells, endosomal acidification inhibitors can be added prior to or
shortly after inoculation of the cells with PCV2.
[0073] According to one aspect, the present invention provides
methods for the cultivation of viruses, whereby increased virus
titres are obtained, which is of interest e.g. in the production of
vaccines. The average titre of virus in a medium of infected cells
is between 3.4 and 4.5 log.sub.10 TCID.sub.50/ml. Using the methods
of the present invention, the concentration of an animal circular
ssDNA virus in an undiluted culture medium, can raise up to a titre
of 4.8 to 5.7 log.sub.10 TCID.sub.50/ml or more. Thus, the present
invention relates to an improvement of the cultivation of animal
circular ssDNA virus which ensures an increase in titre of
approximately 1.3 log.sub.10 TCID50/ml or more. It is demonstrated
herein that using the methods of the invention, titres
corresponding to titres representative of industrial production can
be obtained.
[0074] The production of virus-containing cell cultures according
to the present invention can be carried out in different scales,
such as in flasks, roller bottles or bioreactors. The media used
for the cultivation of the cells to be infected are known to the
skilled person and will comprise the standard nutrients required
for cell viability but may also comprise additional nutrients
dependent on the cell type. Optionally, the medium can be
protein-free. Depending on the cell type the cells can be cultured
in suspension or on a substrate.
[0075] Thus, one aspect of the invention relates to circular animal
ssDNA virus, which can be isolated from a medium and/or infected
cells after cultivation according to the present invention. The
isolated virus can be used to obtain one or more of the viral
proteins or to isolate the viral DNA therefrom.
[0076] The purification and isolation of circular animal ssDNA
virus is known by the skilled person and is described for example
by Meehan et al. (1998) J. Gen. Virol. 79, 2171-2179. Protection of
swine against post-weaning multi-systemic wasting syndrome by PCV2
proteins has been demonstrated (Blanchard et al. (2003) Vaccine 21,
4565-4575).
[0077] Alternatively, the isolated virus can be used as such in the
production of an attenuated or inactivated virus for vaccination.
Attenuation of virus strains for use in vaccination is performed by
different methods, including repeated passaging on cells,
particularly on cell lines, such as PK/15 or by activation of
virus-associated endonuclease (Schodeller et al. J. Gen. Virol.,
65, 1567-1573). Inactivation of a virus can be achieved by using
chemical methods, e.g. by exposing the antigen to a chemical agent
such as formaldehyde (formalin), paraformaldehyde,
beta.-propiolactone or ethyleneimine or its derivatives (Larghi et
al. (1980) J. Clin Microbiol 11, 120-122); US patent application
2002/0146432), or by UV-irradiation.
[0078] Thus, one aspect of the present invention relates to a
method for the preparation of a vaccine against a circular animal
ssDNA virus, which encompasses the cultivation of the virus in
accordance with the methods of the present invention. A vaccine
according to the present invention can comprise either an
immunogenic agent or a compound which, upon introduction into the
host, ensures the production of an immunogenic agent. Thus a
vaccine can comprise DNA, RNA, or protein material, or both,
including the complete virus.
[0079] In a particular embodiment the vaccine is a vaccine for the
prevention of postweaning multisystemic wasting syndrome (PMWS) in
pigs caused by PCV2 strains such as strain Stoon-1010. In another
particular embodiment the vaccine is a vaccine for the prevention
of the abortion of pigs caused by the abortion-associated PCV2
strain 1121. In another particular embodiment the vaccine is a
vaccine for the prevention of hepatitis-like disorders caused by
Anelloviruses such as TT virus.
[0080] Besides the immunogenic agent or the compound which ensures
the production of the immunogenic agent in vivo, vaccines generally
comprise a vehicle or diluent acceptable from the veterinary point
of view, optionally an adjuvant acceptable from the veterinary
point of view, as well as optionally a freeze-drying stabilizer.
When comprising attenuated virus particles, vaccines will generally
comprise from 10.sup.3.0 to 10.sup.6.0 TCID50 (50% tissue culture
infective dose). Inactivated vaccines can be supplemented with
adjuvant, advantageously by being provided in the form of
emulsions, for example water-in-oil or oil-in-water, according to
techniques well known to persons skilled in the art. It will be
possible for the adjuvant character to also come from the
incorporation of a customary adjuvant compound into the active
ingredient. Among the adjuvants which may be used, there may be
mentioned by way of example aluminium hydroxide, the saponines
(e.g. Quillaja saponin or Quil A; see Vaccine Design, The Subunit
and Adjuvant Approach, 1995, edited by Michael F. Powel and Mark J.
Newman, Plennum Press, New-York and London, p. 210), Avridine.RTM.
(Vaccine Design p. 148), DDA (Dimethyldioctadecyl-ammonium bromide,
Vaccine Design p. 157), Polyphosphazene (Vaccine Design p. 204), or
alternatively oil-in-water emulsions based on mineral oil, squalene
(e.g. SPT emulsion, Vaccine Design p. 147), squalene (e.g. MF59,
Vaccine Design p. 183), or water-in-oil emulsions based on
metabolizable oil (preferably according to WO-A-94 20071) as well
as the emulsions described in U.S. Pat. No. 5,422,109 or those
described in WO-A-9416681. It is also possible to choose
combinations of adjuvants, for example Avridine.RTM. or DDA
combined with an emulsion. As freeze-drying stabilizer, there may
be mentioned by way of example SPGA (Bovarnik et al., J.
Bacteriology 59, 509), carbohydrates such as sorbitol, mannitol,
starch, sucrose, dextran or glucose, proteins such as albumin or
casein, derivatives of these compounds, or buffers such as alkali
metal phosphates.
[0081] Another aspect of the present invention relates to the
provision of a method for diagnosing an infection of animal
circular ssDNA virus in a sample, whereby the sensitivity of the
detection is increased. These methods are of interest in the
detection of postweaning multisystemic wasting syndrome (PMWS) or
susceptibility thereto, as pigs with high PCV2 replication have
been shown to be more likely to develop PMWS than pigs with low
PCV2 replication (Segales and Domingo, 2002, Vet Q. 2002 September;
24(3):109-24). The sample used in the detection methods according
to this aspect of the present invention. Such a sample can be
either a cell-containing sample (which as used herein refers to a
sample comprising cells which are susceptible to animal circular
ssDNA virus) or a sample which itself does not comprise cells which
are susceptible to infection with circular ssDNA virus (e.g.
supernatant of a cell culture). Typically, the sample will be
either a cell-containing or non cell-containing sample of an animal
or a cell culture. The detection can either be performed on the
sample or on a fraction thereof, but for simplification purposes
the methods of the invention will generally refer to the sample.
The increase in sensitivity of detection is obtained by increasing
the amount of virus before detection using interferon and/or
inhibiting endosomal-lysosomal system acidification as described
herein. This increase in amount of virus can be achieved in the
sample directly, whereby detection of the ssDNA virus can also be
performed on the sample directly. Alternatively, the increase in
amount of virus is achieved after addition of the sample to a cell
culture susceptible to animal circular ssDNA virus infection and
ensuring the medium of the cell culture contains or is contacted
with interferon and/or conditions inhibiting endosomal/lysosomal
system acidification. This can be ensured by addition of interferon
or an interferon inducing agent to the medium of the cell culture
or by ensuring that the cell culture endogenously produces
interferon. Additionally or alternatively, this is ensured by
addition of one or more endosomal/lysosomal acidification
inhibitors to the cell culture or by ensuring that the cell culture
endogenously generates an increased pH in the lysosomes or other
organelles within the endosomal-lysosomal system (e.g. as a result
of genetic modification of a gene involved in endosomal/lysosomal
acidification). When a cell culture susceptible to animal circular
ssDNA virus infection is used, detection of the presence of ssDNA
virus is performed on the cells or the medium of the cell
culture.
[0082] Thus, according to a first embodiment of this aspect of the
invention, the sample is e.g. a cell-comprising sample of an
animal, such as a blood sample. Addition of an IFN, or an agent
capable of inducing IFN production (by the cells in the sample) to
the sample of the animal, is used to obtain an increase in
virus-titre in the sample such that the sensitivity of the
detection of the circular ssDNA virus in the sample is increased.
Agents capable of inducing IFN in e.g. blood cells are described
herein. Additionally or alternatively, addition of an agent capable
of inhibiting endosomal/lysosomal acidification or an agent which
indirectly ensures reduction of acidification in the
endosomal-lysosomal system is used to ensure in an increase in
virus-titre in the sample, similarly resulting in an increased
sensitivity of detection. Where both interferon and reduction of
endosomal/lysosomal acidification are used, a synergistic effect on
sensitivity is obtained.
[0083] According to another embodiment of this aspect of the
invention, the sample (which can be a sample which does not contain
cells, such as serum or cell culture supernatant) is contacted with
a cell culture which is susceptible to infection by a circular
ssDNA virus, to which the interferon and/or agent inhibiting
endosomal/lysosomal acidification is then added. Alternatively, the
production of interferon by the cell culture used can be ensured,
either by selecting an appropriate IFN producing cell line or by
genetic modification of a susceptible cell line. Similarly, a cell
line with altered acidification of the endosomal/lysosomal system
can be used. Detection of the circular ssDNA virus is performed on
the medium or the cells of the cell culture. Such a detection can
be performed both qualitatively and/or quantitatively based on the
detection of the presence of viral DNA, viral proteins or the
detection of infectious virus. Again, cultivation according to the
methods of the invention will induce a higher virus titre such that
the sensitivity of the detection is increased. According to this
aspect of the invention the cell cultures susceptible to animal
circular ssDNA virus infection can be a continuous cell line or can
be a primary cell culture such as a culture of PBML's.
[0084] According to yet another aspect of the invention interferon
and/or inhibitors of endosomal-lysosomal system acidification are
used to mediate the response of animals, more specifically pigs or
humans to the vaccination with an attenuated circular ssDNA virus.
Attenuated viruses are modified viruses which still replicate in
the host but are no longer (or less) virulent, and can be obtained
as described herein. According to this aspect interferon and/or
inhibitors of endosomal-lysosomal system acidification are used to
increase the replication of attenuated PCV2 in vivo and thus to
enhance the immune response to the virus upon administration to an
animal. Administration of the interferon and/or inhibitors of
endosomal-lysosomal system acidification to the animal can be done
separately (i.e. before, during or after administration of the
virus vaccine) or together with the virus. Thus one aspect of the
invention relates to a vaccine comprising both an animal circular
ssDNA virus and interferon and/or inhibitors of endosomal-lysosomal
system acidification.
[0085] The following Examples, not intended to limit the invention
to specific embodiments described, may be understood in conjunction
with the accompanying Figures:
[0086] FIG. 1. Influence of cytokines on number of PCV2-infected
PK-15 cells according to one embodiment of the invention. [0087]
Black bar: effect of cytokines administered before inoculation;
grey bar: during inoculation; white bar: post inoculation. All
results represent the mean of three independent
experiments+standard error of the mean.
[0088] FIG. 2. Light microscopic pictures of the influence of
IFN-gamma treatment on the number of PCV2 positive cells in PK-15
and 3D4/31 cells according to one embodiment of the invention.
Pictures A and C show the number of PCV2 positive cells in
respectively PK-15 and 3D4/31 cells. Pictures B and D show the
number of PCV2 positive cells in respectively PK-15 and 3D4/31
cells treated with 500 U/ml IFN-gamma respectively after and before
inoculation. All pictures are taken at a magnification of
100.times..
[0089] FIG. 3. Influence of cytokines on number of PCV2-infected
3D4/31 cells according to one embodiment of the invention. [0090]
Black bar: effect of cytokines administered before inoculation;
grey bar: during inoculation; white bar: post inoculation. All
results represent the mean of three independent
experiments+standard error of the mean.
[0091] FIG. 4. Progeny virus production in PK-15 cells treated with
500 U/ml IFN.gamma. compared to non-treated cells according to one
embodiment of the invention. Full lines represent the titres
obtained in PCV2-inoculated PK-15 cultures supplemented with 500 U
IFN-.gamma. per ml. Dashed lines represent titres obtained in PK-15
cultures without IFN-.gamma.. Lines with black circles represent
extracellular virus titres, lines with black cubes represent
intracellular titres. Lines without symbols represent total PCV2
titres.+-.standard error of the mean.
[0092] FIG. 5. Effect of interferon-gamma on attachment of
recombinant PCV2-capsid virion-like particles to 3D4/31 cells
according to one embodiment of the invention. [0093] Black blocks
represent the number of virion-like particles attached at different
time points after inoculation tot non-treated [0094] 3D4/31 cells.
White blocks represent the results obtained in [0095] 3D4/31 cells
treated with 500 l/ml IFN-gamma during incubation of the
virion-like particles with the cells. The results represent the
average number of virion-like particle attached to 10 different
cells.+-.standard deviation.
[0096] FIG. 6. Effect of naturally induced interferons on
PCV2-infection in PK-15 cells according to one embodiment of the
invention; Effect of BAL-fluids of PRCV and mock-inoculated pigs
(A) and supernatant of ConA and mock-stimulated PBMC's (B) on the
number of PCV2-infected PK-15 cells.
[0097] FIG. 7. Effect of endosomal-lysosomal system acidification
inhibitors and/or IFN-gamma on the number of PCV2-infected PK-15
cells. PK-15 cells were pre-treated with (black bars) or without
IFN-gamma (white bars) for 24 hours before they were inoculated
with the same dose of PCV2. After PCV2 inoculation, cells were
treated with (ammonium chloride, chloroquine diphosphate and/or
monensin) or without (control) endosomal-lysosomal system
acidification inhibitors for 24 hours. The number of PCV2-infected
cells in all treatment combinations was counted after 36 hours
incubation and compared with the number of PCV2-infected cells in
non-treated cells.
[0098] FIG. 8. Total PCV2 virus titres in PK-15 cells treated with
IFN-gamma and/or inhibitors of endosomal-lysosomal system
acidification; 25 mM ammonium chloride, 125 .mu.M chloroquine
diphosphate and/or 6 .mu.M monensin.
EXAMPLES
General methodology
[0099] Cells, Virus and Inoculation
[0100] PK/15 is a pig kidney epithelial cell culture derived from
embryonic pigs, which is known to be uncontaminated with the
porcine circovirus (PCV), pestiviruses, porcine adenoviruses and
porcine parvoviruses [Allan G. et al. (1995) Vet. Microbiol. 44,
49-64].
[0101] PK-15 cells were seeded and maintained in culture medium
containing 5%-10% fetal bovine serum (FBS), 0.3 mg/ml glutamine,
100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.1 mg/ml kanamycin
dissolved in minimal essential medium (MEM) (Gibco BRL.RTM., Grand
Island, USA) or dissolved in RPMI-1640 (GIBCO BRL.RTM., Grand
Island, USA) containing 1% nonessential amino acids (100.times.;
GIBCO BRL.RTM., Grand Island, USA) and 1 mM sodium pyruvate (GIBCO
BRL.RTM., Grand Island, USA). Cells were seeded at a concentration
of 150,000 cells per ml of medium. For the detection of total viral
antigen positive cells, the cells were seeded in 96-well microtiter
plates (Nunc) (15,000-20,000 cells per well). To detect the
expression of specific viral antigens, cells were seeded on sterile
cover slips in Leighton tubes (150,000 cells per tube) and finally
progeny virus production assays were performed in 24-well plates
containing 15,000 cells per well.
[0102] In order to use cells, more related to the target cells in
vivo, the monocytic cell line 3D4/31 was used to confirm the effect
of the different cytokines on the number of PCV2-infected cells.
The 3D4/31 cell line is a porcine monomyeloid cell lines that was
established following transfection of primary porcine alveolar
macrophage cultures with plasmid pSV3neo, carrying genes for
neomycin resistance and SV40 large T antigen. (Weingartl et al.
(2002) J Virol Methods. 10, 203-216). These cells were maintained
in a 1:1 mixture of RPMI-1640 (Invitrogen) and DMEM (Invitrogen)
supplemented with 10% fetal bovine serum, 0.3 mg/ml glutamine, 100
U/ml penicillin, 0.1 mg/ml streptomycin, 0.1 mg/ml kanamycin and 1%
non-essential amino acids 100.times. (GIBCO BRL.RTM., Grand Island,
USA). These experiments were also performed in 96-well plates
containing the same number of cells. Furthermore, to monitor the
effect of IFN-gamma on the entry of PCV2 virion-like particles was
determined, 3D4/31 cells were seeded at 2.times.10.sup.5 cells/ml
of medium onto microscopic slides mounted with an 8 well cell
culture silicone chamber (Vivascience AG, Hanover). In all
inoculations, the same PCV2-strain (Stoon-1010) was used at a
multiplicity of infection of 0.01. The virus was diluted in MEM and
inoculated on the cell cultures by incubating cells and virus for 1
hour at 37.degree. C. After 1 hour, the inoculum was removed, the
cultures were washed twice with MEM and new culture medium was
added.
[0103] Cytokines and Neutralizing Antibodies
[0104] Porcine interleukin 1 (IL-1), interleukin 6 (IL-6),
interleukin 10 (IL-10), and interferon gamma (IFN-gamma) were all
purchased from the same company (R&D systems). The activity of
the preparations is indicated on the leaflets supplied with the
product. In case of IFN-gamma the activity is measured in an
anti-viral assay using porcine PK-15 cells infected with EMC virus.
The ED50 for this effect is typically 0.015-0.045 ng/mL.
[0105] Porcine recombinant interferon alpha (IFN-alpha) was kindly
provided by Dr. Charley [Lefebvre F. et al. (1990) J Gen Virol. 71,
1057-1063]. Tumour necrosis factor alpha (TNF-alpha) was produced
in L929 cells transfected with the pBMGNeo expression-vector
containing the TNF.alpha. coding cDNA (Von Niederhausern et al.
(1993) Vet Immunol Immunopathol, 38, 57-73). IL-1, IL-6, IL-10 and
IFN-gamma were dissolved according to the manufacturers'
instructions in lipopolysaccharide free phosphate buffered saline
(PBS) supplemented with 0.1% bovine serum albumin (Sigma, Bornem,
Belgium) to a concentration of 10 .mu.g/ml. Subsequently, the
cytokines were diluted in MEM supplemented with 10% FBS to a
concentration eight times higher than the highest final
concentration used in the assays.
[0106] IFN-alpha neutralizing antibodies (K9) were kindly provided
by Dr. Charley.
[0107] Statistical Analysis
[0108] All experiments were repeated three times independently. The
results presented herein represent the mean value obtained from
these tree experiments. The variation between different experiments
is represented by the standard error of the mean (SEM). Differences
were considered to be significant when p<0.05. (p-value
calculated with the Mann-Whitney test).
Example 1
Influence of Cytokines on the Total Number of PCV2-Infected
Cells
[0109] The influence of the cytokines on the infection of PCV2 in
PK-15 and 3D4/31 cells was determined by adding two-fold-dilution
series of the cytokines to the medium of the cells before, during
or after the inoculation. IL-1, IL-6, IL-10 and IFN-alpha were used
in concentrations ranging from 0.25-250 Units/ml (U/ml), IFN-gamma
was used in concentrations ranging from 0.25-1000 U/ml and IL-10
was used in concentrations from 0.13-125 U/ml. Cell cultures were
either pre-treated with the cytokines for 24 hours before
inoculation, treated during the inoculation or the cytokines were
added in the medium after the inoculation. After 36 hours of
incubation at 37.degree. C. in an environment supplemented with 5%
CO2, the cells were fixed by drying and frozen at -20.degree. C.
The plates were stained with an immuno-peroxydase monolayer assay
(IPMA) as described by Sanchez et al. (2003, Vet Microbiol 95,
15-25) and the number of PCV2-positive cells was counted by light
microscopy. In each plate a control was inoculated with an equal
dose of mock-treated PCV2 (treated with MEM without cytokines). The
number of infected cells in this well was used as the reference and
all results were expressed as a ratio to this reference.
[0110] Influence of Cytokines on the Total Number of PCV2-Infected
PK-15 Cells
[0111] The results of the effects of dilution series of different
cytokines in PK-15 cells are shown in FIG. 1. With TNF-alpha, IL-1,
IL-6 and IL-10, no significant change in the number of
PCV2-positive cells was observed at any concentration or for any
time of treatment (before, during or after inoculation). With both
interferons (IFN-alpha and IFN-gamma) a clear effect was
observed.
[0112] IFN-gamma induced a dose-dependent increase in the number of
PCV2-antigen positive cells disregarded of the time point when it
was added to the medium of the cells (before, during of after the
inoculation). The highest effect was seen with the highest
concentration tested in the experiment (1000 U/ml). When this
concentration of IFN-gamma was supplemented to the medium before
inoculation, an increase in positive cell of 518.+-.134% was
observed, when it was added to the medium during inoculation, an
increase of 270.+-.57% was observed and the highest effect was
observed when it was added to the medium after the inoculation,
which induced an increase of 791.+-.105%.
[0113] The lowest concentration of IFN-gamma which induced a
significant increase of PCV2-positive cells when administered
before, during or after inoculation, were respectively 16, 2 and 2
U/ml). FIG. 2 shows a picture of light microscopic views of PK-15
cells without IFN (negative controls) and with 500 U/ml IFN-gamma
added in the medium after the inoculation.
[0114] IFN-alpha induced a similar increase of positive cells when
administered during or after inoculation, but it induced a
significant reduction of infected cells when the cells were
pre-treated. At the highest concentration used (250 U/ml) an
increase of 341.+-.114% and 629.+-.59% was observed when added
respectively during or after the inoculation. After pre-treatment,
a reduction of 31.+-.6% was observed. The lowest concentrations of
IFN-alpha inducing a significant effect when added before, during
or after PCV2-inoculation were respectively 31, 16 and 8 U/ml). The
effects induced by treatment of cells with IFN-alpha could be
neutralized when IFN-alpha was incubated for 1 hour at 37.degree.
C. with IFN-alpha-neutralizing antibodies, prior to incubation with
the cells.
[0115] Influence of Cytokines on the Total Number of PCV2-Infected
3D4/31 Cells
[0116] In 3D4/31 cells, TNF-alpha, IL-1, IL-6 and IL-10, did not
induce a significant change in the number of PCV2-positive cells at
any concentration or at any time of treatment (before, during of
after inoculation). Similar observation were made in these cells
compared to PK-15 cells when the 3D4/31 cells were treated with
IFN-alpha and IFN-gamma. IFN-gamma induced a dose-dependent
increase in the number of PCV2-positive cells when cells were
treated before, during or after the inoculation. A maximal increase
of respectively 806.+-.88%, 214.+-.16% and 523.+-.115% was
observed. When cells were treated with IFN-alpha before
inoculation, no significant changes were observed. When IFN-alpha
was administered to the cells during or after inoculation, an
increase in positive cells of respectively 115.+-.10% and
408.+-.35% was detected. The results of these experiments are
presented in FIG. 3.
Example 2
Influence of IFN-Gamma on the Production of PCV2
[0117] Since IFN-gamma increased the number of PCV2-positive PK-15
cells independent of the time when it was added to the medium of
the cells, this cytokine was selected to investigate the effect in
the production of progeny virus at a concentration of 500 U/ml.
[0118] The influence of IFN-gamma on the production of progeny
virus in PCV2-infected cells was determined by inoculating PK-15
cells with the standard PCV2-stock. After the inoculation, culture
medium was added supplemented with IFN-gamma (500 U/ml). At 0, 12,
24, 36, 48 and 72 hours post inoculation (hpi) the supernatant was
collected. Subsequently the culture was washed once with 1 ml PBS.
Both the supernatant and the washing fluid were centrifuged for 10
minutes at 15,000.times.g to pellet cells and debris. The
centrifuged supernatant and washing fluids were combined and
considered to contain the extracellular virus. Both pellets and
cell cultures were freeze-thawed tree times and considered to
contain the intracellular virus. Intra- and extracellular virus
titres were determined by titration on PCV-negative PK-15 cells as
described previously.
[0119] The results of the production experiment is presented in
FIG. 4. Both extracellular and intracellular virus production was
increased in the IFN-gamma treated cells compared to the
non-treated control cells. The total PCV2 production in cells
treated with IFN-gamma at 72 hpi was 1.3 log.sub.10 TCID.sub.50
higher compared to the non-treated cells.
Example 3
Influence of IFN-Gamma on the Expression Kinetics of PCV2
Proteins
[0120] To determine the timing and localisation of PCV2 proteins
expression (Capsid protein and REP), PK-15 cells were seeded on
glass cover slips and inoculated with PCV2. After inoculation,
culture medium was added with or without 500 U/ml IFN-gamma. At 0,
12, 24, 36, 48 and 72 hpi the cells were fixed in methanol at
-20.degree. C. Afterwards, a triple immunofluorescence staining was
performed to visualize both viral proteins and the cell nucleus.
PCV2 capsid protein was detected using purified biotinylated
porcine polyclonal anti-PCV2 immunoglobulins which only react with
PCV2 capsid proteins. Bound porcine immunoglobulins were visualized
with streptavidin conjugated Texas Red (molecular probes, Leiden,
The Netherlands). In a second step, the REP protein was detected
with a specific mouse monoclonal antibody (F210) visualized with
goat-anti-mouse FITC (molecular probes, Leiden, The Netherlands).
In a final step, the nuclei of the cells were visualized with
Hoechst 33342 (Molecular Probes, Oregon, USA) at a concentration of
0.1 mg/ml. The number of cells with capsid and/or REP protein was
counted and the localisation of viral antigens was monitored by
fluorescence microscopy.
[0121] Treatment of PK-15 cells did not influence the sequence of
events considering the expression of PCV2 proteins. Capsid and REP
proteins were detected for the first time at respectively 12 and 24
hpi in treated and non-treated cells. The first nuclear
localisation of both proteins was observed at 24 hpi in both
cultures in a similar proportion of cells.
Example 4
Influence of IFN-Gamma on the Infectious Cycle of PCV2
[0122] Since IFN-gamma induced the most constant increase in number
of positive cells both in PK-15 cells as in 3D4/31 cells, this
cytokine was selected for studies on the influence of interferons
on the infectious cycle of PCV2.
[0123] a) Influence of IFN-Gamma on the Attachment of PCV2 Capsids
on 3D4/31 Cells
[0124] The attachment of PCV2 capsids onto untreated 3D4/31 cells
and 3D4/31 cells pre-treated with IFN-gamma was studied as
described by Misinzo et al. (J Gen Virol. conditionally accepted
for publication). Briefly, treated and untreated 3D4/31 cells were
chilled on ice and washed before PCV2 capsids were added and
allowed to attach for 0, 1, 5, 10, 15, 30 and 60 minutes at
4.degree. C. Unbound PCV2 capsids were washed-off and cells were
fixed with 3% (w/v) paraformaldehyde in phosphate-buffered saline
with calcium and magnesium (PBS+) at room temperature for 10
minutes. In order to stain the PCV2 capsids, cells were incubated
with biotin-conjugated anti-PCV2 swine polyclonal antibodies and
streptavidin-FITC (Molecular Probes, Leiden, The Netherlands) for 1
hour at room temperature. The slides were mounted and analysed by
acquisition of digital images of stained PCV2 capsids using a Leica
TCS SP2 laser scanning spectral confocal system (Leica Microsystems
GmbH, Heidelberg, Germany) linked to a Leica DM/IRB inverted
microscope (Leica Microsystems GmbH, Wetzlar, Germany). Successive
images from the apex to the base of a single cell were taken and
merged. The number of PCV2 capsids attached per cell was counted
for ten cells at each time point to establish their binding
kinetics into 3D4/31 cells.
[0125] No differences were observed in the number of attached
virion-like particles per 3D4/31 cell, nor on the kinetics of
virion binding to the cells as presented in FIG. 5. Both in the
treated and non-treated cells, the number of attached virions cells
increased quickly within 5 minutes and reached a maximum at 15
minutes after incubation. Attached virions were observed on all
cells both treated and non-treated as described before.
[0126] b) Influence of IFN-Gamma on the Entry of PCV2
[0127] To study the internalization of recombinant capsids on
3D4/31, cells were washed with RPMI-1640 at 37.degree. C. and then
incubated with capsids at 37.degree. C. for 15 minutes followed by
washing of unbound capsids. Cells were then fixed with a 3%
solution of paraformaldehyde (rPBS) for 10 minutes at 30, 60 and
120 minutes since the addition of capsids into the cells, washed
with PBS, and permeabilized in a 0.1% Triton X-100 solution in
rPBS. Capsids were stained by incubating the calls with a
biotin-conjugated anti-PCV2 swine polyclonal antibody followed by
streptavidin-FITC (Molecular Probes, Eugene, Oreg.).
[0128] A significant increase in the number of internalized virions
was observed when 3D4/31 cells were treated with IFN-gamma.
Example 5
Influence of IFN-Gamma on the Number of Infectious Particles
Required for the Infection of PK-15 Cells
[0129] PCV2 infectious titres are generally determined by
inoculating 10-fold dilution series on PK-15 cells, followed by a
staining of PCV2-positive cells. In this experiment it was
investigated if the treatment of PK-15 cells with IFN-gamma before,
during or after the inoculation, could increase the sensitivity of
the PCV2-titration assay. PK-15 cells were treated with IFN-gamma
(500 U/ml) as described above. Subsequently, a PCV2 stock with a
known infectious titre was titrated both on treated cells and on
non-treated cells. After 72 hours of incubation after inoculation,
the cells were fixed and the total number of PCV2-positive cells
was determined with the IPMA as described above. The titres
obtained in IFN-gamma-treated and non-treated PK-15 cells were
compared.
[0130] The number of infectious particles needed for infection of
PK-15 cells was investigated by titrating a PCV2-stock of a known
infectious titre in non-treated (control) and IFN-gam ma-treated
cells. In non-treated cells the titre of the stock varied between
3.8 and 4.1 log.sub.10 TCID.sub.50/ml. When IFN-gamma was added to
the medium after the inoculation of the stock, the titre varied
between 5.3 and 5.8 log.sub.10 TCID.sub.50/ml. This indicates that
between 1.2 and 2.0 log.sub.10 times less infectious PCV2 particles
were required for infection of PK-15 cells when they were treated
with 500 U/ml IFN-gamma.
Example 6
Effect of Natural Sources of Porcine Cytokines on PCV2-Infection in
PK-15 Cells
[0131] Natural Sources of Porcine Cytokines
[0132] Two natural sources of interferons were included. First,
peripheral blood monocytes (PBMC's) were isolated from blood of a
conventional 4-week-old pig by differential centrifugation on
Ficoll Paque.RTM.. These monocytes were cultured in medium as
described earlier (Verfaillie et al. (2002) Vet Immunol
Immunopathol 81, 97-112) and stimulated with 5 .mu.g/ml
concanavalin A (ConA) (Sigma). Simultaneously, a culture of PBMC's
was incubated in the same medium without ConA. After 16 hours of
incubation at 37.degree. C. in the presence of 5% CO2, the
supernatant was collected and centrifuged to remove cells
(Verfaillie et al., above). The concentration of IFN.gamma. in
these supernatants was respectively 20.5 U/ml and below the
detection limit as determined by a porcine IFN.gamma.-specific
ELISA (Biosource, Nijvel, Belgium).
[0133] Second, 20 times concentrated bronchiolar lavage fluid
(BAL-fluid) were collected at 1 day post inoculation from
gnotobiotic pigs experimentally inoculated with porcine respiratory
coronavirus (PRCV) or mock-inoculated pigs. The BAL-fluid of the
PRCV-inoculated pig had previously been determined to contain
174650 U/ml IFN.alpha., 56 U/ml IFN.gamma., >20480 U/ml IL6 and
273 U/ml TNF.alpha., the BAL-fluid of the mock-inoculated pig
contained no detectable levels of IFN.alpha., IFN.gamma. and
TNF.alpha. and contained 87 U/ml IL6.
[0134] Influence of Natural Sources of Porcine Cytokines on the
Total Number of PCV2-Infected Cells
[0135] Two-fold dilutions of the BAL-fluids of the PRCV and
mock-inoculated pigs were added to the medium of PCV2-inoculated
PK-15 cells after inoculation. Concentrations of the added
BAL-fluids ranged from 1.25 to 5%. Supernatants of ConA and
mock-stimulated PBMC's were also added to the culture medium of
PK-15 cells after inoculation in concentrations ranging from 6.15
to 50%. After 36 hours of incubation, PK-15 cultures were fixed and
stained as described above and the number of infected cells was
determined.
[0136] The results of these experiments are shown in FIG. 6. When
5% of the 20.times. concentrated BAL fluids of a PRCV-inoculated
gnotobiotic pig were added to PK-15 cells after PCV2-inoculation,
an increase in PCV2-positive cells of 745.+-.39% was observed.
Lower concentrations of this BAL-fluid showed that the effect was
dose-dependent. The BAL-fluid of the mock-inoculated gnotobiotic
pig did not influence the number of PCV2-positive cells.
[0137] The supernatant of ConA-stimulated PBMC's also caused a
dose-dependent increase in PCV2-positive cells when it was added to
the medium of PCV2-inoculated PK-15 cells. When a concentration of
50% of this supernatant was added to the cells, an increase of
215.+-.22% was observed. Again the supernatant of non-stimulated
PBMC's did not influence the number of PCV2-infected cells.
Example 7
Effect of Interferon on the Immune Response to the Vaccination with
an Attenuated Circular ssDNA Virus
[0138] If interferons would increase the replication of PCV2 in
vivo, it would probably also increase the replication of attenuated
PCV2 and by that mechanism enhance the immune response of the pig
to the virus.
[0139] Pigs are inoculated with PCV2 (field strain Imp-1121) at 19
days of age. These inoculated pigs are divided in 3 groups. One
group contains control pigs (only PCV2). The second group of pigs
receives recombinant IFN-gamma (100,000 Upper pig every three
days). The third group contains pigs that receive ConA (1.5 mg/kg
every three days). At different times post inoculation (10.mu., 15,
21 days) samples are collected and the replication of the virus is
assessed.
[0140] An increase in the replication of PCV2 is detected in pigs
injected with IFN-gamma or ConA compared to the control pigs. From
this it can be concluded that IFN has a similar effect on
PCV2-replication in vivo.
Example 8
Effect of Endosomal-Lysosomal System Acidification Inhibitors on
PCV2 Infection of PK-15 Cells
[0141] Endosomal-lysosomal system acidification was inhibited using
lysosomotropic weak bases (ammonium chloride and chloroquine
diphosphate) and carboxylic ionophore monensin. All chemical
compounds were purchased from Sigma. In a first set of experiments,
a two-fold dilution of each inhibitor in PK-15 cells using
Stoon-1010 was performed to determine the highest concentration of
each inhibitor that exerted the maximal effect without affecting
cell viability. Finally, 25 mM ammonium chloride, 125 .mu.M
chloroquine diphosphate and 6 .mu.M monensin were chosen. PK-15
cells were cultivated for 24 hours and then inoculated with a dose
of PCV2 for 1 hour at 37.degree. C. The viral inoculum was
washed-off and cells were further incubated in culture medium with
or without inhibitors of endosomal-lysosomal acidification for 24
hours. Then, the culture medium containing endosomal-lysosomal
system inhibitors was replaced with fresh culture medium without
inhibitors. After the first cycle of PCV2 replication, at 36 hpi,
cells were fixed with methanol at -20.degree. C. for 10 minutes.
Cells were stored at -20.degree. C. until they were stained using
an immunoperoxidase monolayer assay (IPMA) as described by Sanchez
et al. (2003, Vet Microbiol 95, 15-25).
[0142] Results:
[0143] The effect of endosomal-lysosomal system acidification
inhibitors on PCV2 infection of PK-15 cells is shown in FIG. 7
(white bars). Agents that inhibit endosomal-lysosomal system
acidification, ammonium chloride, chloroquine diphosphate and
monensin, enhance PCV2 infection compared to control.
Example 9
Synergistic Effect of Endosomal-Lysosomal System Acidification
Inhibitors and IFN-Gamma on PCV2 Infection of PK-15 Cells
[0144] Endosomal-lysosomal system acidification was inhibited using
lysosomotropic weak bases (ammonium chloride and chloroquine
diphosphate) and carboxylic ionophore monensin as described in
Example 8 in the following concentrations: 25 mM ammonium chloride,
125 .mu.M chloroquine diphosphate and/or 6 .mu.M monensin. PK-15
cells were pre-treated with or without 500 U/ml IFN-gamma for 24
hours before they were inoculated with the same dose of PCV2 for 1
hour at 37.degree. C. The viral inoculum was washed-off and cells
were further incubated in culture medium containing inhibitors of
endosomal-lysosomal acidification for 24 hours. Then, the culture
medium containing endosomal-lysosomal system inhibitors was
replaced with fresh culture medium without inhibitors. After the
first cycle of PCV2 replication, at 36 hours post-inoculation cells
were fixed with methanol at -20.degree. C. for 10 minutes. Cells
were stored at -20.degree. C. until they were stained using an
immunoperoxidase monolayer assay (IPMA) as described above. The
number of infected cells per well in mock-treated cells inoculated
with an equal dose of PCV2 as treated cells was used as the
referent, and all results are expressed as a percentage of this
referent. All experiments were performed three times, and each
condition in a single experiment was performed in duplicate.
[0145] Results:
[0146] Agents that inhibit endosomal-lysosomal system
acidification, ammonium chloride, chloroquine diphosphate and
monensin, enhanced PCV2 infection in IFN-gamma treated cells (FIG.
7, black bars). The effect of endosomal-lysosomal system
acidification inhibitors was synergistic to that exerted by
IFN-gamma, indicating that they increased PCV2 infection via
different mechanisms.
Example 10
Synergistic Effect of Endosomal-Lysosomal System Acidification
Inhibitors and IFN-Gamma on Progeny PCV2 Production
[0147] For progeny virus production assays, 2.times.10.sup.5 cells
were seeded in every well of 24-well cell culture plates. Cells
were pre-treated with or without 500 U/ml IFN-gamma at 6 hours post
seeding. At 24 h post-seeding, cells were washed and inoculated
with the prototype PCV2 strain Stoon-1010 at an m.o.i. of 0.3 for 1
hour at 37.degree. C. The viral inoculum was washed-off and cells
were further incubated in 1 ml of culture medium with or without 25
mM ammonium chloride, 125 .mu.M chloroquine diphosphate and/or 6
.mu.M monensin for 24 hours. Then, the culture medium with or
without endosomal-lysosomal system acidification inhibitors was
replaced with fresh culture medium without inhibitors. At 1, 24, 48
and 72 hours post-inoculation the supernatant was collected.
Subsequently the culture was washed once with 1 ml PBS. Both the
supernatant and the washing fluid were centrifuged for 10 minutes
at 15,000.times.g to pellet cells and debris. The centrifuged
supernatant and washing fluids were combined and considered to
contain the extracellular virus. Both pellets and cell cultures
were freeze-thawed three times and considered to contain the
intracellular virus. Intra- and extracellular virus titres were
determined by titration on PCV-negative PK-15 cells as described
previously. Viral antigens were detected using an IPMA as described
above and PCV2 titre was expressed as log.sub.10 TCID.sub.50 per
10.sup.5 cells.
[0148] Results:
[0149] PCV2 production was increased by treatment of the cells with
endosomal-lysosomal system acidification inhibitors and/or
IFN-gamma treatment. A synergistic increase in virus production was
observed when cells were treated with a combination of
endosomal-lysosomal system acidification inhibitors and IFN-gamma
(Table 1).
[0150] The total PCV2 virus titres in PK-15 cells treated with
interferon-gamma and inhibitors of endosomal-lysosomal system
acidification is provided in Table 1 and illustrated in FIG. 8.
TABLE-US-00001 TABLE 1 Total PCV2 virus titres in PK-15 cells
treated with or without 500 U/ml IFN-gamma and/or lysosomotropic
agents that inhibit endosomal-lysosomal system acidification. IFN-
PCV2 titres (TCID.sub.50 per 10.sup.5 cells at gamma . . .
Lysosomotropic agent (U/ml) 1 hpi 24 hpi 48 hpi 72 hpi Control 0
1.9 1.5 2.9 3.1 Control 500 2.0 2.1 3.4 3.9 Ammonium chloride 0 2.1
1.9 3.0 3.8 Ammonium chloride 500 1.6 3.0 4.0 4.8 Chloroquine
diphosphate 0 1.4 1.8 3.3 4.3 Chloroquine diphosphate 500 1.6 2.3
4.0 4.6 Monensin 0 1.9 2.3 3.9 3.6 Monensin 500 2.0 2.8 4.6 4.8
[0151] All publications and patents mentioned in this specification
are herein incorporated by reference to the same extent as if each
individual publication or patent was specifically and individually
indicated to be incorporated by reference.
[0152] From the foregoing description, one skilled in the art can
easily ascertain the essential characteristics of this invention,
can make various changes and modifications of the invention to
adapt it to various usages and conditions. Thus, other embodiments
are also within the claims.
* * * * *